Special Issue "Biocompatible Materials in Drug Delivery System in Oncology"

A special issue of Pharmaceutics (ISSN 1999-4923).

Deadline for manuscript submissions: 29 February 2020.

Special Issue Editors

Dr. Flavio Rizzolio
E-Mail Website
Guest Editor
Department of Molecular Science and Nanosystems, Università Ca' Foscari Venezia, Venice, Italy
Interests: cancer therapy; signaling pathways; precision medicine; drug delivery system
Special Issues and Collections in MDPI journals
Dr. Isabella Caligiuri
E-Mail Website
Guest Editor
Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
Interests: cancer; molecular pathology; nanomedicine

Special Issue Information

Dear Colleagues,

Nanomedicine is a growing arena of exciting discoveries with the promise to cure different deadly pathologies. In particular, the drug delivery field has been attracted many attentions from the first discovery of the enhanced permeability effect in tumor in the early 80’s. From passive to active targeting strategies have been applied to better tailored Drug Delivery Systems for each pathology. Although these efforts, only a few are of success such as liposomal doxorubicin and albumin paclitaxel. Among possible explanations of these low rate of success are the type of animal models utilized, no patient stratifications based on the genomic characteristics, a reductionistic approach considering only cancer cells and no consideration of the current standard therapy.
This Special Issue of Pharmaceutics will attempt to cover the recent advancements in the application of Drug Delivery System in Oncology.

Dr. Flavio Rizzolio
Dr. Isabella Caligiuri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • drug delivery systems
  • personalized therapy
  • cancer
  • animal models
  • tumor microenvironment

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells
Pharmaceutics 2020, 12(2), 96; https://doi.org/10.3390/pharmaceutics12020096 (registering DOI) - 24 Jan 2020
Abstract
Multidrug resistance (MDR) is a critical hindrance to the success of cancer chemotherapy. The main thing responsible for MDR phenotypes are plasma-membranes associated with adenosine triphosphate (ATP) Binding Cassette (ABC) drug efflux transporters, such as the P-glycoprotein (Pgp) transporter that has the broadest [...] Read more.
Multidrug resistance (MDR) is a critical hindrance to the success of cancer chemotherapy. The main thing responsible for MDR phenotypes are plasma-membranes associated with adenosine triphosphate (ATP) Binding Cassette (ABC) drug efflux transporters, such as the P-glycoprotein (Pgp) transporter that has the broadest spectrum of substrates. Curcumin (CURC) is a Pgp inhibitor, but it is poorly soluble and bioavailable. To overcome these limitations, we validated the efficacy and safety of CURC, loaded in biocompatible solid lipid nanoparticles (SLNs), with or without chitosan coating, with the goal of increasing the stability, homogeneous water dispersibility, and cellular uptake. Both CURC-loaded SLNs were 5–10-fold more effective than free CURC in increasing the intracellular retention and toxicity of doxorubicin in Pgp-expressing triple negative breast cancer (TNBC). The effect was due to the decrease of intracellular reactive oxygen species, consequent inhibition of the Akt/IKKα-β/NF-kB axis, and reduced transcriptional activation of the Pgp promoter by p65/p50 NF-kB. CURC-loaded SLNs also effectively rescued the sensitivity to doxorubicin against drug-resistant TNBC tumors, without signs of systemic toxicity. These results suggest that the combination therapy, based on CURC-loaded SLNs and doxorubicin, is an effective and safe approach to overcome the Pgp-mediated chemoresistance in TNBC. Full article
(This article belongs to the Special Issue Biocompatible Materials in Drug Delivery System in Oncology)
Open AccessArticle
Effects of Focused-Ultrasound-and-Microbubble-Induced Blood-Brain Barrier Disruption on Drug Transport under Liposome-Mediated Delivery in Brain Tumour: A Pilot Numerical Simulation Study
Pharmaceutics 2020, 12(1), 69; https://doi.org/10.3390/pharmaceutics12010069 - 15 Jan 2020
Abstract
Focused ultrasound (FUS) coupled with microbubbles (MB) has been found to be a promising approach to disrupt the blood-brain barrier (BBB). However, how this disruption affects drug transport remains unclear. In this study, drug transport in combination therapy of liposomes and FUS-MB-induced BBB [...] Read more.
Focused ultrasound (FUS) coupled with microbubbles (MB) has been found to be a promising approach to disrupt the blood-brain barrier (BBB). However, how this disruption affects drug transport remains unclear. In this study, drug transport in combination therapy of liposomes and FUS-MB-induced BBB disruption (BBBD) was investigated based on a multiphysics model. A realistic 3D brain tumour model extracted from MR images was applied. The results demonstrated the advantage of liposomes compared to free doxorubicin injection in further improving treatment when the BBB is opened under the same delivery conditions using burst sonication. This improvement was mainly due to the BBBD-enhanced transvascular transport of free doxorubicin and the sustainable supply of the drug by long-circulating liposomes. Treatment efficacy can be improved in different ways. Disrupting the BBB simultaneously with liposome bolus injection enables more free drug molecules to cross the vessel wall, while prolonging the BBBD duration could accelerate liposome transvascular transport for more effective drug release. However, the drug release rate needs to be well controlled to balance the trade-off among drug release, transvascular exchange and elimination. The results obtained in this study could provide suggestions for the future optimisation of this FUS-MB–liposome combination therapy against brain cancer. Full article
(This article belongs to the Special Issue Biocompatible Materials in Drug Delivery System in Oncology)
Show Figures

Graphical abstract

Back to TopTop